Active Cancer Cells, Biochemistry & Physiology

Drug Discovery and Team Science

In plain English

AI plain-English summary

A new training programme will embed PhD students in multidisciplinary teams, each tackling a specific disease—cancer, pain, respiratory illness, immune-oncology, or inflammation—by combining lab experiments with mathematical modelling. The pharmaceutical industry has identified critical skills gaps in complex animal models and in translating lab findings into real treatments. Most researchers train in a single discipline, but drug discovery requires chemists, biologists, and data scientists to work together from the start. This programme directly addresses that gap by making team science the core of the training, not an afterthought. If successful, the programme will produce a generation of scientists who can move seamlessly between academic labs and industry, accelerating the development of drugs that target membrane receptors—proteins on cell surfaces that are key to many diseases. This could shorten the time from a fundamental discovery to a medicine that reaches patients. The programme also embeds placements in pharmaceutical companies and small biotech firms, so students learn translational skills—communication, leadership, entrepreneurship—that are rarely taught in traditional PhDs. The result is a workforce better equipped to turn biological insights into treatments that change lives.

View original technical description
This programme focuses on the application of a multidisciplinary Team Science approach to develop novel approaches and technologies involving the physical, biological and medical sciences to study membrane receptors in the right cell type and tissue. The programme embraces colleagues from UoN, pharmaceutical companies, SMEs and learned societies to develop a training programme that has the student at its centre but which engenders a collaborative multidisciplinary approach within a cohort-based programme of research. Each entry of four students will study one of the following disease-related themes: (a) cancer angiogenesis; (b) pain and addition; (c) respiratory diseases; (d) immune-oncology and (e) inflammation. Each cohort will tackle their given disease theme as a multidisciplinary team, with each student working in one of four key experimental areas: (a) Target engagement; (b) cellular environment; (c) in vivo and ex vivo models and (d) mathematical modelling and systems biology. The key programme goals will address: (1) the major skills gaps identified by ABPI in complex in vivo experimental models and in vitro pharmacological analytical approaches; (2) the need for multidisciplinary programmes, industrial/transitional placements and the provision of training in ‘translational’ skills such as communication, leadership and entrepreneurship; and (3) the need for supportive training environments.

View the original record at the funder ↗

Researchers

Jeanette Woolard (EPMC Awardee)Lucy Donaldson (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

EPSRC Centre for Doctoral Training in Synthesis for Biology and Medicine
An in vitro sensor integrated blood brain barrier model for the investigation of circadian transport of xenobiotics into the brain
PhD Programme at the Institute of Cancer Research: Programme in Mechanism- Based Drug Discovery.
Next-Generation Sensing For Human In Vivo Pharmacology- Accelerating Drug Development In Inflammatory Diseases
EPSRC Centre for Doctoral Training in Advanced Therapeutics & Nanomedicines

Original classification

PhD Programme in Science (Basic)

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.